UBS AM’s Janux Therapeutics JANX Stock Holding History

UBS AM’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$907K	Sell	59,019 -28,738	-33%	-$416K	﹤0.01%	2372
2026 Q1	$1.22M	Buy	87,757 +12,259	+16%	+$168K	﹤0.01%	2260
2025 Q4	$1.04M	Buy	75,498 +9,173	+14%	+$216K	﹤0.01%	2121
2025 Q3	$1.62M	Sell	66,325 -45,037	-40%	-$1.1M	﹤0.01%	1834
2025 Q2	$2.57M	Sell	111,362 -75,032	-40%	-$1.98M	﹤0.01%	2036
2025 Q1	$5.03M	Buy	186,394 +20,657	+12%	+$779K	﹤0.01%	1571
2024 Q4	$8.87M	Buy	165,737 +139,543	+533%	+$7.38M	﹤0.01%	1307
2024 Q3	$1.19M	Sell	26,194 -3,984	-13%	-$173K	﹤0.01%	2309
2024 Q2	$1.26M	Buy	30,178 +21,483	+247%	+$1.01M	﹤0.01%	2254
2024 Q1	$327K	Buy	+8,695	New	+$189K	﹤0.01%	2384

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

UBS AM's JANX Position: Q2 2026 in Review

UBS AM reduced its Janux Therapeutics (JANX) stake by 33% in Q2 2026, selling an estimated $416K and leaving 59,019 shares worth $907K. The position accounts for ﹤0.01% of the portfolio, ranked #2372.

UBS AM first reported a position in JANX in Q1 2024 and has held it in 10 quarters since. The position peaked at $8.87M in Q4 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

UBS AM held 59,019 shares of Janux Therapeutics worth $907K as of Q2 2026.
UBS AM sold 28,738 Janux Therapeutics shares in Q2 2026, an estimated $416K.
Janux Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2372 holding.
UBS AM first reported a position in Janux Therapeutics in Q1 2024 and has held it in 10 quarters since.
UBS AM's Janux Therapeutics position peaked at $8.87M in Q4 2024.
198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.